Dianthus Therapeutics, Inc.
DNTHFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Dianthus Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Dianthus Therapeutics, Inc. — 10-K filed Mar 9, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 10 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| NEUBERGER BERMAN GROUP LLC | 2026-03-31 | 59,076 | $4.96M | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 634 | $53.2K | SEC filing |
| Cannon Global Investment Management, LLC | 2026-03-31 | 5,100 | $428K | SEC filing |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2026-03-31 | 65,238 | $5.47M | SEC filing |
| Legal & General Group Plc | 2026-03-31 | 21,627 | $1.81M | SEC filing |
| ABS Direct Equity Fund LLC | 2026-03-31 | 2,000 | $179K | SEC filing |
| PFM Health Sciences, LP | 2026-03-31 | 172,137 | $14.4M | SEC filing |
| Parkside Financial Bank & Trust | 2026-03-31 | 1,050 | $88.1K | SEC filing |
| ELEVATION POINT WEALTH PARTNERS, LLC | 2026-03-31 | 4,872 | $409K | SEC filing |
| Spruce Street Capital LP | 2026-03-31 | 373,274 | $31.3M | SEC filing |
| BRAIDWELL LP | 2026-03-31 | 899,364 | $75.5M | SEC filing |
| Alyeska Investment Group, L.P. | 2026-03-31 | 52,247 | $4.38M | SEC filing |
| VICTORY CAPITAL MANAGEMENT INC | 2026-03-31 | 15,662 | $1.31M | SEC filing |
| Invesco Ltd. | 2026-03-31 | 130,747 | $11M | SEC filing |
| KLP KAPITALFORVALTNING AS | 2026-03-31 | 8,900 | $747K | SEC filing |
| Kemnay Advisory Services Inc. | 2026-03-31 | 398 | $33.4K | SEC filing |
| Artia Global Partners LP | 2026-03-31 | 162,990 | $13.7M | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 1,610,483 | $135M | SEC filing |
| VOYA INVESTMENT MANAGEMENT LLC | 2026-03-31 | 6,077 | $510K | SEC filing |
| Legato Capital Management LLC | 2026-03-31 | 12,532 | $1.05M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Dianthus Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-31 · Savitz Ryan: Larger than 38 of the 42 other insider sales of Common Stock on file. SEC filing
- 2026-03-12 · Garcia Marino: Larger than 39 of the 42 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · Randhawa Simrat: Larger than 40 of the 42 other insider sales of Common Stock on file. SEC filing
- 2023-02-08 · TRV GP IV, LLC: Larger than 41 of the 42 other insider sales of Common Stock on file. SEC filing
- 2023-02-07 · TRV GP IV, LLC: Larger than all 42 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2023-09-22–2023-09-29: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )
- 2023-09-19–2023-09-26: 4 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-17 | Veness Adam M · SVP, General Counsel and Sec. | Common Stock | S — Open market or private sale | −16,771 | 80.34 | SEC filing |
| 2026-06-17 | Veness Adam M · SVP, General Counsel and Sec. | Common Stock | S — Open market or private sale | −13,229 | 81.38 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Common Stock | S — Open market or private sale | −16,943 | 90.72 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Common Stock | S — Open market or private sale | −5,428 | 89.72 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Common Stock | S — Open market or private sale | −4,159 | 91.37 | SEC filing |
| 2026-05-08 | Soteropoulos Paula · Director | Common Stock | S — Open market or private sale | −599 | 85.47 | SEC filing |
| 2026-04-09 | Savitz Ryan · EVP, CFO & CBO | Common Stock | S — Open market or private sale | −8,224 | 89.84 | SEC filing |
| 2026-03-31 | Savitz Ryan · EVP, CFO & CBO | Common Stock | S — Open market or private sale | −7,232 | 85.54 | SEC filing |
Showing 8 of 18 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | Veness Adam M · SVP, General Counsel and Sec. | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −30,000 | SEC filing |
| 2026-06-17 | Veness Adam M · SVP, General Counsel and Sec. | Common Stock | M — Exercise or conversion of derivative security | +30,000 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −3,998 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Common Stock | M — Exercise or conversion of derivative security | +9,375 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Common Stock | M — Exercise or conversion of derivative security | +6,908 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Common Stock | M — Exercise or conversion of derivative security | +3,998 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −6,249 | SEC filing |
| 2026-06-01 | Randhawa Simrat · EVP, Head of R&D | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −9,375 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-09-27 | Fairmount Funds Management LLC · Director | Common Stock | J — Other acquisition or disposition | −62,146 | SEC filing |
| 2024-04-01 | Fairmount Funds Management LLC · Director | Common Stock | J — Other acquisition or disposition | −58,857 | SEC filing |
| 2024-04-01 | Fairmount Funds Management LLC · Director | Common Stock | J — Other acquisition or disposition | +58,857 | SEC filing |
| 2021-08-26 | Borisy Alexis · Director | Common Stock | J — Other acquisition or disposition | +4,100 | SEC filing |
| 2021-08-25 | TRV GP IV, LLC · 10% owner | Common Stock | J — Other acquisition or disposition | −1,250,000 | SEC filing |
| 2021-02-11 | Atlas Venture Fund X, L.P. · 10% owner | Common Stock | J — Other acquisition or disposition | −968,726 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.